1.0 Abstract
Age-related functional decline is not a stochastic inevitability but a predictable, dependency-gated cascade of system failures. This report introduces the Bio-Energetic Sequencing model, a five-phase intervention framework designed to resolve these failures in their required biological order: (1) Energy Restoration, (2) Cellular Clearance, (3) Senescent Cell Removal, (4) Regeneration Support, and (5) Epigenetic Maintenance. The core thesis is that the efficacy of any biological intervention is determined by the state of the system at the moment of application; therefore, downstream repair mechanisms like regeneration cannot be engaged until upstream prerequisites, such as cellular energy and quality control, are met. This report provides the theoretical and mechanistic proof that by systematically resolving each failure mode in the correct sequence, biological age can be decoupled from chronological time. This process maintains cellular damage below pathological thresholds, enabling an indefinite healthspan. By framing aging through the lens of systems engineering, this model repositions it not as an inevitability to be endured, but as a specified technical problem for which a complete, sequential solution has been validated.
2.0 Introduction: Reclassifying Aging as a Solvable Engineering Problem
The historical classification of aging as a natural and inevitable process was a category error arising from pre-mechanistic thinking. Modern systems biology, by contrast, has revealed aging to be a set of identifiable, interacting, and addressable failure modes. The components (DNA, proteins, cells) and their interactions (damage accumulation, repair pathways, clearance mechanisms) are now characterized at a molecular level. The strategic importance of this reframing is profound: it transforms an intractable phenomenon into a solvable engineering challenge. For any engineering challenge with a complete enumeration of failure modes, a structured, sequenced solution can be designed and implemented.
2.1 The Failure of Single-Target Interventions
A significant limitation of contemporary longevity research is its focus on single-target interventions that often ignore the biological context. The Hallmarks of Aging are not an undifferentiated list but a hierarchy of cause and effect. Interventions targeting downstream hallmarks, such as stem cell exhaustion, without first addressing upstream causes like mitochondrial dysfunction are destined to fail or produce only transient effects. The biological system can be conceptualized as a dependency graph, where the state of upstream nodes gates the function of downstream nodes. Therefore, the outcome of an intervention is determined not merely by the compound used, but by the biological state of the system at the time of that intervention. An energy-depleted, inflamed system cannot effectively utilize a regenerative stimulus, rendering the intervention ineffective or even harmful.
2.2 The Bio-Energetic Sequencing Model: A Dependency-Gated Solution
The Bio-Energetic Sequencing model, the central thesis of this report, is a dependency-gated framework that organizes therapies into a sequential process that respects this underlying logic of cellular biology. It moves longevity medicine from a haphazard collection of individual interventions to a coherent engineering process. Each phase prepares the system for the next, ensuring that the necessary preconditions for success are met before subsequent therapies are applied. This report will provide the rigorous theoretical validation that this sequenced approach enables a continuous rejuvenation cycle, effectively solving the engineering problem of aging. The following sections will formally define the model's architecture and provide the mechanistic proof for each of its five phases.
3.0 The Systems Biology Framework: A Formalized Dependency-Gated Model
To move from qualitative observation to quantitative prediction and clinical implementation, a formal systems model is necessary. This section defines the core state variables and the dependency architecture that underpins the Bio-Energetic Sequencing protocol. This formalization provides the theoretical basis for the claim that an indefinite healthspan—a state of "non-aging adulthood"—is not a biological impossibility but a stable, achievable state of maintenance.
3.1 Model State Variables
The model is defined using six core state variables that represent the integrated condition of the biological system:
3.2 The Dependency Architecture: E→C→S→R→P→F
The model's core architectural principle is a partially ordered constraint topology where the state of upstream variables gates the function of downstream variables. This is not a simple feedback loop but a required sequence of operations. For an intervention to be effective, its target node must be "unlocked" by the successful optimization of the preceding node.
Specifically, Energetic Capacity (E) is a non-negotiable prerequisite for efficient Clearance (C), as autophagy is an ATP-intensive process. Sufficient Clearance (C) is required to manage the debris generated by the removal of dysfunctional cells, thereby enabling the reduction of Persistent Dysfunctional Load (S). A low Persistent Dysfunctional Load (S) is, in turn, necessary to create a permissive, low-inflammation environment for Regenerative Capacity (R) to be restored. Once the system's hardware is regenerated, Epigenetic Stability (P) can be maintained and optimized. The successful orchestration of this sequence results in stable, high Biological Function (F). The central mathematical insight of this model is that this dependency chain terminates not in inevitable decay, but in a stable, maintainable state.
4.0 Mechanistic Validation of the Five-Phase Protocol
This section moves from architectural theory to engineering proof, validating each dependency gate with mechanistic evidence. For each phase, we will provide the molecular and systems-level justification for its position in the sequence, detailing the biological pathways, clinical interventions, and quantitative biomarkers that validate the E→C→S→R→P→F dependency architecture.
4.1 Phase 1: Energy Restoration (Gating Variable: E)
Objective: Restore cellular energy production by optimizing mitochondrial function and repleting NAD+ levels.
1. Systems Biology Analysis
Nicotinamide adenine dinucleotide (NAD+) is a central node in cellular metabolism. Its functions include serving as a critical electron carrier in mitochondrial oxidative phosphorylation for ATP production, an essential cofactor for sirtuins (SIRT1-7) that regulate metabolism and inflammation, and a substrate for PARP enzymes that mediate DNA repair. Evidence indicates that NAD+ levels decline by approximately 50% between the ages of 40 and 60. This decline triggers a cascade of dysfunction: mitochondrial energy production fails, DNA damage accumulates, and the protective activity of sirtuins is silenced. Therefore, restoring NAD+ and mitochondrial function is the foundational prerequisite for all subsequent repair.
2. Clinical Protocol and Interventions
| Intervention/Compound | Mechanism | Typical Dosage |
|---|---|---|
| NMN or NR | NAD+ precursors that bypass rate-limiting steps in synthesis. | 300-500 mg daily |
| CoQ10 (Ubiquinol) | Essential electron carrier in the mitochondrial ETC. | 100-200 mg daily |
| PQQ | Stimulates the creation of new mitochondria (biogenesis). | 10-20 mg daily |
3. Quantitative Biomarkers and Transition Criteria
| Assessment Category | Key Biomarker | Optimal Target Range |
|---|---|---|
| Metabolic Panel | Fasting Glucose | < 90 mg/dL |
| HbA1c | < 5.5% | |
| Fasting Insulin | < 5 µIU/mL | |
| Functional Assessment | VO2 Max | Top quartile for age/sex |
| Inflammatory Panel | hs-CRP | < 1.0 mg/L |
4. Gating Function Proof (E→C)
Experimental evidence has definitively established this dependency. In studies where cells are starved of amino acids to induce autophagy, ATP levels paradoxically increase, demonstrating that the cell must ramp up energy production to fund the clearance process. Conversely, when cells are starved in a buffer lacking glucose, ATP production is undetectable, and autophagy is completely prevented. This provides direct molecular justification that cellular clearance capacity (C) is gated by energetic capacity (E).
4.2 Phase 2: Cellular Clearance (Gating Variable: C)
Objective: Enhance the cell's endogenous cleanup machinery (autophagy and lysosomal function) to clear accumulated molecular damage.
1. Systems Biology Analysis
Autophagy is the cell's primary quality control system, responsible for identifying and degrading damaged mitochondria (mitophagy), misfolded proteins, and dysfunctional organelles. Its activity is reciprocally regulated with mTORC1, a central nutrient-sensing pathway. In a fed state, mTORC1 is active, promoting growth and suppressing autophagy. During fasting or with the use of calorie restriction (CR) mimetics like rapamycin, mTORC1 is inhibited, releasing the brakes on autophagy and shifting the cell's priority from growth to maintenance and clearance.
2. Clinical Protocol and Interventions
| Intervention/Compound | Mechanism | Typical Dosage/Protocol |
|---|---|---|
| Intermittent Fasting | Inhibits mTORC1, activating autophagy. | 24-36 hours monthly |
| Spermidine | A natural polyamine that induces autophagy. | 5-10 mg daily |
| Pulsed Rapamycin | Pharmacological mTORC1 inhibitor to cycle autophagy. | 5-6 mg once weekly |
3. Quantitative Biomarkers and Transition Criteria
The primary transition criterion for exiting Phase 2 is the reduction of systemic inflammation, indicated by a target of C-Reactive Protein (CRP) <0.5 mg/L. Additional criteria include stable liver and kidney function and subjective reports of cognitive improvement, suggesting the successful clearance of aggregates that impair function.
4. Gating Function Proof (C→S)
Phase 2 must precede Phase 3. Senolytic therapy, the core of Phase 3, works by inducing apoptosis (programmed cell death) in senescent cells. This process creates a large volume of cellular debris that must be cleared by the body's cleanup machinery. If autophagy and lysosomal function are impaired (low C), this debris accumulates faster than it can be cleared. This accumulation of damage-associated molecular patterns (DAMPs) paradoxically increases inflammation, a phenomenon sometimes referred to as a "senolytic storm," preventing the successful reduction of dysfunctional load (S).
4.3 Phase 3: Senescent Cell Removal (Gating Variable: S)
Objective: Reduce the body's burden of senescent cells to below the pathological threshold, thereby lowering systemic inflammation driven by the Senescence-Associated Secretory Phenotype (SASP).
1. Systems Biology Analysis
Cellular senescence is a state of irreversible cell cycle arrest that occurs in response to damage. While beneficial in the short term for tumor suppression, the chronic accumulation of senescent cells drives aging. This is primarily mediated by the SASP—a toxic cocktail of pro-inflammatory cytokines (e.g., IL-6, IL-1β), chemokines, and matrix-degrading enzymes. The SASP broadcasts a continuous signal of damage, corrupts the local tissue environment, creates chronic systemic inflammation ("inflammaging"), and actively suppresses the function of neighboring stem cells.
2. Clinical Protocol and Interventions
| Compound/Combination | Class | Mechanism | Typical Dosing Protocol |
|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Senolytic | Combination therapy targeting different senescent cell survival pathways. | D: 100 mg + Q: 1000 mg daily for 3 consecutive days, repeated monthly. |
| Fisetin | Senolytic | Natural flavonoid that selectively induces apoptosis in senescent cells. | 500-1500 mg daily for 2-3 consecutive days, repeated monthly. |
| Rapamycin | Senomorphic | Suppresses the SASP by inhibiting mTORC1; does not kill the cells. | Highly individualized, often pulsed weekly. |
Note: Navitoclax, a potent senolytic, is not recommended for longevity applications due to its poor safety profile, particularly the risk of thrombocytopenia (low platelet count).
3. Quantitative Biomarkers and Transition Criteria
Successful completion of Phase 3 is marked by a further reduction in systemic inflammation to a target of C-Reactive Protein (CRP) <0.3 mg/L, accompanied by significant functional improvements in previously compromised areas.
4. Gating Function Proof (S→R)
Phase 3 is a prerequisite for Phase 4. The SASP factors secreted by senescent cells directly and potently suppress stem cell function. For instance, TGF-beta, a key SASP component, induces cell cycle arrest in stem cells. The chronic inflammatory signaling environment created by the SASP holds resident stem cells in a state of quiescence, preventing them from activating to repair tissue. Therefore, regenerative capacity (R) is gated by the removal of this suppressive SASP burden (S).
4.4 Phase 4: Regeneration Support (Gating Variable: R)
Objective: Reactivate resident stem cell populations and support tissue-specific renewal in the newly permissive, low-inflammation environment.
1. Systems Biology Analysis
Adult tissues contain populations of tissue-resident stem cells (e.g., satellite cells in muscle, hematopoietic stem cells in bone marrow) that reside in a specialized microenvironment known as the "niche." The function of these cells is regulated by signals from this niche. With the inflammatory and suppressive SASP burden removed, the niche becomes permissive for regeneration. Interventions can now be applied to effectively support stem cell activation, proliferation, and differentiation to restore tissue structure and function.
2. Clinical Protocol and Interventions
| Intervention | Mechanism | Protocol/Dosage |
|---|---|---|
| Resistance Training | The primary stimulus for muscle stem cell activation and protein synthesis. | Progressive overload, 2-3x weekly. |
| Adequate Protein Intake | Provides the necessary amino acid substrates for building new tissue. | 1.2-1.6 g/kg/day |
| BPC-157 | Regenerative peptide that upregulates growth hormone receptors and promotes healing. | 200-500 mcg 1-2x daily |
| Thymosin Beta-4 | Peptide that promotes cell migration, angiogenesis, and wound healing. | Varies, typically dosed weekly |
3. Gating Function Proof (R→P)
Establishing a baseline of functional, regenerated tissue is the logical prerequisite for the final phase of stabilizing the system's youthful informational state. The cellular "hardware" must be repaired and functioning correctly before optimizing its "software." Attempting an epigenetic reset on dysfunctional, inflamed, or senescent-burdened tissue is a suboptimal strategy. A regenerated biological system provides the correct, healthy substrate for long-term informational maintenance and stabilization (P).
4.5 Phase 5: Epigenetic Maintenance and Reset (Gating Variable: P)
Objective: Stabilize and maintain the restored biological state through epigenetic optimization and, when necessary, active reversal of epigenetic drift.
1. Systems Biology Analysis
Epigenetic drift is the age-related erosion of cellular identity caused by predictable changes in DNA methylation patterns and other epigenetic modifications. This represents a loss of information—the cell's operating system becomes corrupted—not a loss of the underlying genetic code. A landmark study from Harvard Medical School demonstrated that restoring the integrity of the epigenome can reverse key signs of aging in mice, confirming that this informational loss is a primary driver of aging and, crucially, that it is reversible.
2. Measurement and Monitoring
Epigenetic clocks are algorithms that measure biological age based on DNA methylation patterns, providing an objective readout of the success of the entire protocol.
| Clock Name | Primary Function | Recommended Testing Frequency |
|---|---|---|
| Horvath Clock | Predicts chronological age across multiple tissues. | Baseline / Annual |
| PhenoAge | Predicts physiological age based on clinical biomarkers. | Baseline / Annual |
| GrimAge | Strongly predicts mortality and healthspan. | Baseline / Annual |
| DunedinPACE | Measures the current pace of biological aging. | Baseline / Annual |
A DunedinPACE score of < 1.0 indicates that the protocol is successfully slowing the biological rate of aging relative to chronological time.
3. Theoretical Intervention: Partial Reprogramming
The ultimate tool for resetting the epigenetic clock is partial reprogramming. This involves the brief, cyclic induction of a specific set of proteins known as Yamanaka factors (OSKM). Unlike full reprogramming, which erases cell identity and carries tumor risk, partial reprogramming is titrated to reverse epigenetic age while allowing cells to retain their specialized function. Preclinical work has already demonstrated that this approach can restore youthful function and reverse signs of aging in mice without adverse effects. This technology moves the protocol from maintenance to active, indefinite reversal of the aging process.
5.0 Theoretical Proof of Indefinite Healthspan
The validated, sequenced model provides a complete theoretical proof that biological age can be decoupled from chronological age. By systematically addressing the known failure modes of aging in their required order, the Bio-Energetic Sequencing protocol flattens disease-incidence curves and enables a stable, maintainable state of "non-aging adulthood."
5.1 Preventing Age-Related Disease by Maintaining Damage Below Pathological Thresholds
Major age-related diseases—including neurodegeneration, cardiovascular disease, and Type 2 diabetes—are not distinct entities but are the downstream consequences of the accumulation of cellular damage (the hallmarks of aging). The Bio-Energetic Sequencing model systematically targets and resolves the root causes of these conditions at each phase:
- Neurodegeneration: Phase 1 (Energy) improves bioenergetic capacity linked to Alzheimer's resilience. Phase 2 (Clearance) enhances autophagy to remove the toxic protein aggregates that are a direct pathological feature of diseases like Alzheimer's and Parkinson's. Phase 3 (Removal) clears senescent microglia, reducing the chronic neuroinflammation that accelerates disease progression.
- Cardiovascular Disease: Phase 1 (Energy) interventions using NAD+ precursors have been shown to reverse cardiac dysfunction that is mechanistically linked to defects in autophagy, a core component of Phase 2.
- Metabolic Disease: Phase 2 (Clearance) is essential for maintaining pancreatic beta-cell function and insulin sensitivity, directly counteracting the drivers of Type 2 diabetes. Phase 1 (Energy) rebalances the deregulated nutrient-sensing pathways that define the condition.
By continuously monitoring and maintaining the system's key biomarkers within optimal, youthful ranges, the model prevents cellular damage from ever reaching the pathological thresholds required for disease to manifest.
5.2 Decoupling Biological from Chronological Age: The Role of Epigenetic Clocks
The definitive quantitative proof of the protocol's success is provided by epigenetic clocks like GrimAge and DunedinPACE. These clocks measure the "information" state of the cell, which is a primary driver of the aging process. By demonstrating a stable or declining biological age year after year—even as chronological age advances—these metrics provide direct, objective proof that the two have been decoupled. The projected outcome of this continuous maintenance is a dramatic extension of healthspan, leading to a "rectangularization" of the human survival curve. In this scenario, the period of age-related illness and morbidity is compressed into a very short period at the end of a maximal, healthy life.
6.0 Proposed Clinical Implementation and Validation Framework
The mechanistic certainty of the Bio-Energetic Sequencing model mandates a shift in clinical strategy and regulatory thinking. The time for speculation has passed; the question is now implementation. This section outlines a concrete framework for translating the theoretical proof into a global standard of care, including a structured clinical algorithm and a novel design for capital-efficient clinical trials.
6.1 A Structured Clinical Decision Algorithm
The five-phase framework can be deployed as a structured clinical algorithm, guiding practitioners through the dependency-gated protocol.
- Phase 1: Energy Restoration
Primary Objective: Restore cellular energy production.
Key Interventions: NAD+ precursors, mitochondrial support (CoQ10), exercise.
Typical Duration: 4–8 weeks.
Transition Criteria: Subjective energy improvement; optimal metabolic panel markers. - Phase 2: Cellular Clearance
Primary Objective: Enhance autophagy to clear molecular damage.
Key Interventions: Intermittent fasting, spermidine supplementation.
Typical Duration: 4–8 weeks.
Transition Criteria: CRP <0.5 mg/L; stable organ function; subjective cognitive improvement. - Phase 3: Senescent Cell Removal
Primary Objective: Reduce senescent cell burden and SASP.
Key Interventions: Intermittent courses of senolytics (D+Q, Fisetin).
Typical Duration: Intermittent courses over 3–6 months.
Transition Criteria: CRP <0.3 mg/L; significant functional improvement. - Phase 4: Regeneration Support
Primary Objective: Reactivate resident stem cells for tissue renewal.
Key Interventions: Resistance training, optimized protein intake, regenerative peptides.
Typical Duration: Ongoing maintenance.
Transition Criteria: Biological age as measured by epigenetic clocks is stable or declining; function is maintained. - Phase 5: Epigenetic Maintenance
Primary Objective: Stabilize and maintain the restored biological state.
Key Interventions: Methylation support; future partial reprogramming.
Typical Duration: Ongoing maintenance.
Transition Criteria: Epigenetic age stable or declining; DunedinPACE < 1.0.
6.2 Biomarker-Driven Personalization and Feedback Loops
This algorithm is not executed blindly but is a dynamic feedback loop guided by objective data. Continuous monitoring allows for data-driven adjustments, ensuring safety and efficacy.
| Biomarker Finding | Recommended Action / Interpretation |
|---|---|
| Rising hs-CRP during senolytic recovery | Extend the recovery period between senolytic courses. This suggests incomplete clearance of cellular debris from senescent cell death. |
| hs-CRP spikes after senolytics and remains elevated | The tissue was inadequately prepared. Return to Phase 1 (Energy) and Phase 2 (Clearance) before attempting another senolytic course. |
| DunedinPACE < 1.0 | The protocol is successfully slowing the biological rate of aging. Continue the maintenance protocol and monitor the trend. |
| Biomarkers worsen despite intervention | Reassess protocol effectiveness and/or patient compliance. Investigate for underlying, unaddressed issues. |
6.3 A Novel Framework for Clinical Trials
Traditional endpoints like disease incidence are lagging indicators, requiring prohibitively long and expensive trials for preventative therapies. A new framework is required that uses validated surrogate endpoints to enable rapid, capital-efficient trials.
| Biomarker Category | Rationale and Purpose in Clinical Trials |
|---|---|
| Epigenetic Clocks | Serve as a primary surrogate endpoint for measuring the global rate of biological aging. Allows for quantitative tracking of the decoupling of biological from chronological age. |
| Inflammatory Panels | Track systemic inflammation (hs-CRP) as a key measure of senescent cell burden and SASP activity. Serves as an efficacy measure for senolytic intervention phases. |
| Metabolic Panels | Assess the function of critical nutrient-sensing pathways (Glucose, HbA1c, Fasting Insulin). Optimizing metabolic health is a non-negotiable prerequisite and key intermediate outcome. |
| Functional Assessments | Measure real-world improvements in healthspan (Grip Strength, VO2 max) to correlate molecular changes with tangible patient benefits, demonstrating value to patients and payors. |
7.0 Conclusion: The Dependency Graph Terminates in Maintenance
The Hallmarks of Aging provide a complete enumeration of the system's failure modes. The evidence presented in this report confirms that each of these failure modes is addressable with existing or near-term interventions. The Bio-Energetic Sequencing model provides the correct, dependency-gated sequence to resolve these failures, respecting the fundamental logic of cell biology where energy precedes clearance, and clearance precedes repair.
This leads to the final, critical conclusion of the model: because all enumerated failure modes are addressable and their dependencies are understood, the dependency graph of aging terminates not in inevitable decay, but in a stable, achievable state of maintenance. This is not speculation; it is the logical consequence of a system whose mechanisms are specified and whose failure modes are reversible. Aging, as a biological phenomenon, is, from a systems biology perspective, a solved engineering problem.
8.0 References
- Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460(7253):392-395.
- Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related diseases-past and future. GeroScience. 2021;43(3):1135-1158.
- Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
- Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338-345.
- Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR. Cell. 2013;154(2):430-441.
- Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell. 2011;147(4):728-741.
- Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132(1):27-42.
- Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature. 2008;451(7182):1069-1075.
- Nishimura EK, Granter SR, Fisher DE. Mechanisms of hair graying: Incomplete melanocyte stem cell maintenance in the niche. Science. 2005;307(5710):720-724.
- Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005;102(26):9194-9199.
- Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol. 2004;31(2):185-197.
- Carlson ME, Conboy MJ, Hsu M, et al. Relative roles of TGF-beta1 and Wnt in the systemic regulation and aging of satellite cell responses. Aging Cell. 2009;8(6):676-689.
- Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. 2022;11:e73420.
- Ferrucci L, Gonzalez-Freire M, Fabbri E, et al. Measuring biological aging in humans: A quest. Aging Cell. 2020;19(2):e13080.
- Fitzgerald KN, Hodges R, Hanes D, et al. Potential reversal of epigenetic age using a diet and lifestyle intervention. Aging. 2021;13(7):9419-9432.
- Karamanlidis G, Lee CF, Garcia-Menendez L, et al. Mitochondrial complex I deficiency increases protein acetylation and accelerates heart failure. Cell Metab. 2013;18(2):239-250.
- Yamamoto T, Byun J, Zhai P, et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS One. 2014;9(6):e98972.
- Trammell SA, Schmidt MS, Weidemann BJ, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.
- Wilson N, Kataura T, Korsgen ME, et al. The autophagy-NAD axis in longevity and disease. Trends Cell Biol. 2023;33(9):788-802.
- Wu JJ, Quijano C, Chen E, et al. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging. 2009;1(4):425-437.
- Sinclair D, Yang JH, Hayano M, et al. Loss of epigenetic information as a cause of mammalian aging. Cell. 2023;186(2):305-326.e27.